高级搜索
多瑞吉治疗中重度癌症疼痛60 例疗效观察[J]. 肿瘤防治研究, 2007, 34(06): 457-458. DOI: 10.3971/j.issn.1000-8578.579
引用本文: 多瑞吉治疗中重度癌症疼痛60 例疗效观察[J]. 肿瘤防治研究, 2007, 34(06): 457-458. DOI: 10.3971/j.issn.1000-8578.579
Observation on the Eff icacy of Durogesic in Treatment of Sixty Patients with Moderate or Severe Pain[J]. Cancer Research on Prevention and Treatment, 2007, 34(06): 457-458. DOI: 10.3971/j.issn.1000-8578.579
Citation: Observation on the Eff icacy of Durogesic in Treatment of Sixty Patients with Moderate or Severe Pain[J]. Cancer Research on Prevention and Treatment, 2007, 34(06): 457-458. DOI: 10.3971/j.issn.1000-8578.579

多瑞吉治疗中重度癌症疼痛60 例疗效观察

Observation on the Eff icacy of Durogesic in Treatment of Sixty Patients with Moderate or Severe Pain

  • 摘要: 目的 观察多瑞吉(芬太尼透皮贴片)治疗癌症疼痛的疗效及不良反应。方法 应用多瑞吉治疗中重度癌痛患者60例,按数字分级法(NRS)判断疼痛缓解程度,采用癌症病人生活质量评分标准(QOL)评定生活质量变化并观察不良反应。结果 患者疼痛缓解率为98.3%,其中完全缓解25例(41.7%),明显缓解31例(51.7%),生活质量明显改善。不良反应主要为恶心、呕吐、便秘、头晕。结论 多瑞吉治疗中重度癌痛效果确切,不良反应轻,应用方便,可明显改善癌症患者的生活质量。

     

    Abstract: Objective  To observe the response and adverse reactions of Durogesic ( Transdermal Fentanyl) in the t reatment of cancer patients with moderate or severe pain. Methods  Sixty advanced cancer patients with moderate or severe cancer pain were treated with Durogesic. evaluated the pain relief degree according to Numerical Rating Scale (NRS) and investigated the quality of life by the score criterion of Quality of Life (QOL), and observed the adverse reactions. Results  The pain remission rate in cancer patient s of this group was 98. 3 %, including excellent remission rate 41. 7 % and effective remission rate 51. 67 %.The main adverse actions were nausea and vomiting, constipation, and dizziness. Conclusion  Durogesic has significant efficacy, and mild adverse reactions, it is a simple way to using Durogesic for relieving moderate or severe cancer pain. Durogesic can improve the quality of life markedly.

     

/

返回文章
返回